DIABETES | New Drug Approvals
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology | Full Text
The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist - Media Centre | EASD
tirzepatide | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Patrick Holmes 💙 on Twitter: "Tirzepatide. This is a name we are going to hear so much more about. The name for @LillyDiabetes Dual GIP/GLP-1 RA. All post-hoc data from https://t.co/YrQvelF5XF… Points
Supplemental Information – Table & Figures
TIRZEPATIDE (COAGONISTA GIP/GP1): DESARROLLO CLINICO SURPASS
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - The Lancet
Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
cardio-met on Twitter: "From mice models GIP only lowers glucose when glucose close to normal (data not shown) In GLP-1 knockout mice Tirzepatide is much better at weight loss compared to semaglutide
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
Tirzepatide - an overview | ScienceDirect Topics
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes - Media Centre | EASD
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text
Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Structural determinants of dual incretin receptor agonism by tirzepatide | PNAS
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development
